Human Metabolome Technologies, America
Show jobs for this employer
About Human Metabolome Technologies, America
Human Metabolome Technologies (HMT) is a pioneering biotechnology company developing capillary electrophoresis mass spectrometry (CE-MS) based metabolomics technologies and solutions to drive drug development, companion diagnostics, and biomarker discovery. Our research and development methodology are at the heart of an emerging field of metabolomics and systems biology.
Stock symbol: 6090
Stock exchange: TSE
Take a deep dive into HMT metabolomic data using our next generation capillary electrophoresis mass spec platform.
6 articles about Human Metabolome Technologies, America
-
Major Players Operating in the Global Metabolomics Market 2019-2023 | Technavio
7/25/2019
Many investigators and researchers are using metabolomics in the study of chronic diseases such as cancer, which helps them to discover new biomarkers for cancer.
-
Human Metabolome Technologies Begins New Contract With National Institute on Aging, NIH To Study Brain Metabolomic Profiles In Alzheimer's Disease
10/21/2016
-
MYOS Announces Research Agreement With Human Metabolome Technologies America To Conduct Clinical Metabolomic Studies In Subjects Using Fortetropin®
9/18/2014
-
Human Metabolome Technologies Joins National Cancer Institute's OSTR Subsidy Program
7/7/2014
-
Human Metabolome Technologies (HMT) Hires Alexander Buko Ph.D. As Vice President, Business And Product Development And Releases A New C13 Flux Analysis Service, F-SCOPE
6/9/2014
-
Human Metabolome Technologies Expands to U.S., Opening Office in Cambridge, Mass.
11/9/2012